Rivaroxaban for the treatment of deep vein thrombosis and ...

6.4
6.5
analyses conducted by the ERG.
Cost-minimisation analysis, assuming the same treatment effect
between rivaroxaban and LMWH/VKA
Exploratory analysis in cancer patients – examining different HR
7 Overall conclusions 167
8 Appendices 169
9 References 182
Tables
Table 1 Summary of international guidelines and recommendations
(reproduction of Table 3, page 19 of MS)
Table 2 Statement of the decision problem, reproduced from the MS, page 27 17
Table 3 Summary of patient population of studies included in mixed
treatment comparison of LMWH treatment versus VKA treatment in
DVT patients with cancer
Table 4 Rivaroxaban characteristics. Compiled by the ERG using information
given on pages 11 to 13, and in Table 2, page 15 of MS.
Table 5 Summary of outcomes as defined in the NICE scope, as
recommended by the EMA Research Guidelines, and as outlined in
Table 14 and 15 of the MS.
Table 6 Eligibility criteria used in search strategy (reproduction of Table 4,
page 30, in MS)
Table 7 Table showing list of relevant RCTs (reproduced from Table 6 in
MS, p.32)
Table 8 Quality assessment of EINSTEIN-DVT and EINSTEIN-Ext as
reported in MS (Table 17, page 53).
Table 9 Summary of key characteristics of the clinical effectiveness studies
identified in the MS. Data drawn from tables 5, 6, 10, 11 and 14 of
the MS
Table 10 Summary of outcomes for EINSTEIN-DVT, taken from table 18 and
29, data on page 56, 58, 65, 96 of MS 1 and Bauersachs et al. 2011
Table 11 Additional interaction test statistics for the primary analysis of time
to VTE recurrence. Reproduction of Table 1, page 8, manufacturer’s
clarifications
Copyright 2012 Queen's Printer and Controller of HMSO. All rights reserved.
160
162
13
22
23
29
34
38
41
43
50
55